Drug induced parkinsonism Take refrerence from standard books of pharm

Drug induced parkinsonism Take refrerence from standard books of pharmacology

Reading File

Finding Sources

Searching PubMed

drug-induced parkinsonism

Searching the Web

drug induced parkinsonism management standard pharmacology sources dopamine receptor blocking agents

Reading File

Finding Sources

Drug-induced parkinsonism (DIP)

Drug-induced parkinsonism is a reversible secondary parkinsonian syndrome caused mainly by medicines that reduce dopaminergic activity in the nigrostriatal pathway.

Mechanism

Normal motor activity depends on a balance between dopamine and acetylcholine in the corpus striatum.

DIP occurs by either:

Blockade of striatal dopamine D2 receptors
- Reduces dopamine-mediated inhibition of striatal cholinergic activity.
- Produces relative cholinergic overactivity, causing rigidity, bradykinesia, tremor, and postural disturbance.
Depletion of presynaptic monoamine, including dopamine, stores
- Reduces the dopamine available for neurotransmission.

Katzung describes D2 receptor blockade by neuroleptics and antiemetics, and monoamine depletion by reserpine and VMAT2 inhibitors, as key pharmacological mechanisms. Katzung source section

Causative drugs

Mechanism	Important drugs
D2-receptor antagonists	Typical antipsychotics, especially high-potency agents: haloperidol, fluphenazine, trifluoperazine
	Phenothiazines: chlorpromazine, perphenazine, prochlorperazine
	Antiemetics and prokinetics: metoclopramide, prochlorperazine, levosulpiride, droperidol
	Some atypical antipsychotics, particularly risperidone at higher doses
Dopamine/monoamine depleters	Reserpine, tetrabenazine, deutetrabenazine, valbenazine
Other reported drugs	Cinnarizine, flunarizine, methyldopa, lithium, valproate

Clinical features

Usually develops within weeks to 3-4 months of starting the medicine or increasing its dose.
Bradykinesia, rigidity, mask-like facies, decreased arm swing, shuffling gait, stooped posture.
Tremor may occur but is often less prominent than in idiopathic Parkinson disease.
Classically, symptoms are bilateral and symmetric, though asymmetry can occur.
Risk increases with:
- Higher dose and higher potency D2 blockade
- Older age
- Female sex
- Pre-existing Parkinson disease or basal ganglia injury
- Longer treatment exposure

Distinction from idiopathic Parkinson disease

Feature	Drug-induced parkinsonism	Idiopathic Parkinson disease
Relation to medication	Clear temporal association	No drug trigger
Onset	Weeks to months after exposure	Gradual, spontaneous
Symmetry	Usually symmetric	Often asymmetric initially
Rest tremor	Less obvious or absent	Common and often prominent
Course after stopping drug	Often improves over weeks to months	Progressive
Levodopa response	Usually poor while D2 blockade continues	Generally beneficial

Persistence after withdrawal may reflect prolonged drug effects or unmasking of preclinical Parkinson disease.

Management

Identify the causative drug through a full medication history, including antiemetics and prokinetics.
Stop the offending drug if clinically feasible.
If the drug is necessary:
- Reduce to the lowest effective dose.
- Substitute a drug with a lower extrapyramidal-risk profile where appropriate. For antipsychotic treatment, quetiapine or clozapine are commonly preferred alternatives.
Antimuscarinic drugs may relieve symptoms when drug withdrawal is not possible:
- Benztropine
- Trihexyphenidyl
- Biperiden
- Procyclidine
  Avoid or use cautiously in older adults because of confusion, cognitive worsening, dry mouth, constipation, urinary retention, blurred vision, and risk of precipitating angle-closure glaucoma.
Amantadine can be considered when antimuscarinics are unsuitable, especially in older patients.
Levodopa is generally not useful if the dopamine-blocking drug is continued. It can also aggravate psychosis in patients receiving antipsychotics.

Prognosis

Symptoms usually resolve over several weeks to months after stopping the causative medicine. A persistent syndrome warrants reassessment for underlying Parkinson disease or another parkinsonian disorder.

Standard pharmacology reference

The core pharmacology summary above follows Katzung's Basic and Clinical Pharmacology, 16th ed., p. 788: reserpine and VMAT2 inhibitors deplete monoamines; haloperidol, metoclopramide, and phenothiazines block dopamine receptors; DIP is often symmetric, dose-related, and improves after drug withdrawal; antimuscarinics are preferred when treatment must continue.

A 28-year-old female patient, Grace, presents to the Emergency Department by her sister in comatose condition with a respiratory rate of 5 breaths/min, oxygen saturation of 78%, and bilateral pinpoint pupils. Her sister who last spoke with her approximately four hours prior has found an empty prescription bottle of oxycodone 30 mg tablets, filled yesterday with a quantity of 30 tablets next to the patient. Her sister notes a history of severe chronic back pain following a motor vehicle accident of Grace two years ago. She reports that Grace has been increasingly stressed at work and complaining that her current medication dose "isn't touching the pain anymore." Clinician on duty diagnosed this as the "classic case of opioid overdose". a) Identify the classic clinical triad demonstrated in this case and name the specific brain region/receptor interaction responsible for her respiratory depression. (4) b) State the primary pharmacological antidote required, its route of choice in this emergency setting, its mechanism of action, and the specific reason why continuous monitoring is mandatory for the next 4-6 hours. (3) c) Can methadone be helpful in this condition or not? Why? Justify your answer giving proper pharmacological basis. (1) d) Enlist other opioid analgesics used for chronic severe pain/terminal illness. (2) Use standard textbook of pharmacology

Reading File

Finding Sources

Searching PubMed

opioid overdose naloxone

Searching the Web

opioid overdose naloxone duration monitoring recurrence respiratory depression official guidance

The case integrates opioid toxicology and analgesic pharmacology. The key topics are:

Recognition of acute opioid overdose
- Classical toxidrome and immediate airway-breathing priorities.
Mechanism of opioid respiratory depression
- μ-opioid receptor action in brainstem respiratory control centers.
Naloxone in emergency treatment
- Route, mechanism, titration, duration, renarcotization, and monitoring.
Role of methadone
- Why it is not an antidote, despite its role in opioid-use disorder treatment and chronic pain.
Opioid analgesics for severe chronic and cancer pain
- Strong opioid options and relevant clinical distinctions.

At a high level, Grace has an opioid toxidrome: coma, profound hypoventilation, and pinpoint pupils. Immediate management centers on ventilation/oxygenation and naloxone, a competitive opioid receptor antagonist. Monitoring is necessary because naloxone can wear off while the opioid effect remains. Methadone is an opioid agonist, so it does not reverse overdose.

Asking for Preferences

Which part would you like developed as an exam-style answer from standard pharmacology textbooks?

Drug-induced parkinsonism (DIP)

Drug-induced parkinsonism is a reversible secondary parkinsonian syndrome caused mainly by medicines that reduce dopaminergic activity in the nigrostriatal pathway.

Mechanism

Normal motor activity depends on a balance between dopamine and acetylcholine in the corpus striatum.

DIP occurs by either:

Blockade of striatal dopamine D2 receptors
- Reduces dopamine-mediated inhibition of striatal cholinergic activity.
- Produces relative cholinergic overactivity, causing rigidity, bradykinesia, tremor, and postural disturbance.
Depletion of presynaptic monoamine, including dopamine, stores
- Reduces the dopamine available for neurotransmission.

Katzung describes D2 receptor blockade by neuroleptics and antiemetics, and monoamine depletion by reserpine and VMAT2 inhibitors, as key pharmacological mechanisms. Katzung source section

Causative drugs

Mechanism	Important drugs
D2-receptor antagonists	Typical antipsychotics, especially high-potency agents: haloperidol, fluphenazine, trifluoperazine
	Phenothiazines: chlorpromazine, perphenazine, prochlorperazine
	Antiemetics and prokinetics: metoclopramide, prochlorperazine, levosulpiride, droperidol
	Some atypical antipsychotics, particularly risperidone at higher doses
Dopamine/monoamine depleters	Reserpine, tetrabenazine, deutetrabenazine, valbenazine
Other reported drugs	Cinnarizine, flunarizine, methyldopa, lithium, valproate

Clinical features

Usually develops within weeks to 3-4 months of starting the medicine or increasing its dose.
Bradykinesia, rigidity, mask-like facies, decreased arm swing, shuffling gait, stooped posture.
Tremor may occur but is often less prominent than in idiopathic Parkinson disease.
Classically, symptoms are bilateral and symmetric, though asymmetry can occur.
Risk increases with:
- Higher dose and higher potency D2 blockade
- Older age
- Female sex
- Pre-existing Parkinson disease or basal ganglia injury
- Longer treatment exposure

Distinction from idiopathic Parkinson disease

Feature	Drug-induced parkinsonism	Idiopathic Parkinson disease
Relation to medication	Clear temporal association	No drug trigger
Onset	Weeks to months after exposure	Gradual, spontaneous
Symmetry	Usually symmetric	Often asymmetric initially
Rest tremor	Less obvious or absent	Common and often prominent
Course after stopping drug	Often improves over weeks to months	Progressive
Levodopa response	Usually poor while D2 blockade continues	Generally beneficial

Persistence after withdrawal may reflect prolonged drug effects or unmasking of preclinical Parkinson disease.

Management

Identify the causative drug through a full medication history, including antiemetics and prokinetics.
Stop the offending drug if clinically feasible.
If the drug is necessary:
- Reduce to the lowest effective dose.
- Substitute a drug with a lower extrapyramidal-risk profile where appropriate. For antipsychotic treatment, quetiapine or clozapine are commonly preferred alternatives.
Antimuscarinic drugs may relieve symptoms when drug withdrawal is not possible:
- Benztropine
- Trihexyphenidyl
- Biperiden
- Procyclidine
  Avoid or use cautiously in older adults because of confusion, cognitive worsening, dry mouth, constipation, urinary retention, blurred vision, and risk of precipitating angle-closure glaucoma.
Amantadine can be considered when antimuscarinics are unsuitable, especially in older patients.
Levodopa is generally not useful if the dopamine-blocking drug is continued. It can also aggravate psychosis in patients receiving antipsychotics.

Prognosis

Standard pharmacology reference

Recognition of acute opioid overdose
- Classical toxidrome and immediate airway-breathing priorities.
Mechanism of opioid respiratory depression
- μ-opioid receptor action in brainstem respiratory control centers.
Naloxone in emergency treatment
- Route, mechanism, titration, duration, renarcotization, and monitoring.
Role of methadone
- Why it is not an antidote, despite its role in opioid-use disorder treatment and chronic pain.
Opioid analgesics for severe chronic and cancer pain
- Strong opioid options and relevant clinical distinctions.

Classical opioid-overdose triad:

Coma/CNS depression
Respiratory depression: RR 5/min and hypoxaemia
Pinpoint pupils (miosis)

Mechanism: Oxycodone is a predominantly μ-opioid receptor agonist. Activation of μ receptors in the medullary respiratory centres, especially the pre-Bötzinger complex, suppresses inspiratory drive and reduces the ventilatory response to carbon dioxide. This produces slow, shallow breathing that can progress to apnea.

b) Antidote, route, action, and reason for monitoring

Antidote: Naloxone

Route of choice in this emergency: Intravenous (IV) naloxone, because it has the fastest and most titratable effect in a comatose patient with severe respiratory depression. Airway support, oxygenation, and assisted ventilation must be instituted simultaneously. Intramuscular or intranasal naloxone is used if IV access is not immediately available.

Mechanism of action: Naloxone is a pure competitive opioid-receptor antagonist, with high affinity at the μ-opioid receptor. It displaces oxycodone from opioid receptors and rapidly reverses opioid-induced respiratory and CNS depression.

Why continuous monitoring for 4-6 hours is mandatory:
Naloxone has a shorter duration of action than oxycodone and many other opioids. After naloxone is metabolized, residual oxycodone can again activate μ receptors, causing recurrence of sedation and respiratory depression, termed renarcotization. Repeat naloxone doses or a titrated infusion may be required. In large, sustained-release, or long-acting opioid ingestion, observation should be extended beyond 6 hours.

Also monitor for acute opioid withdrawal after naloxone, particularly because Grace may be opioid-tolerant due to chronic oxycodone use.

c) Can methadone help in this acute condition?

No. Methadone must not be used to treat acute oxycodone overdose.

Methadone is a long-acting full μ-opioid receptor agonist. Therefore, it would add to opioid receptor stimulation and may worsen coma and respiratory depression. Its long and variable half-life makes it particularly unsafe in this setting.

Methadone does have a role in:

Chronic severe pain in selected patients
Maintenance treatment of opioid-use disorder
Prevention of opioid withdrawal and reduction of craving

It is not an antidote. Naloxone is the appropriate antagonist for acute opioid poisoning.

d) Other opioid analgesics for chronic severe pain or terminal illness

Common strong opioid analgesics include:

Morphine
Fentanyl - including transdermal fentanyl for stable opioid-tolerant patients with chronic cancer pain
Hydromorphone
Methadone
Oxycodone
Oxymorphone
Buprenorphine - often used transdermally in chronic pain, with specific pharmacological considerations

Morphine remains the standard reference strong opioid for severe cancer and terminal-illness pain, while the choice of alternative depends on prior opioid exposure, renal function, route needed, adverse effects, and pain stability.

These principles are consistent with Goodman & Gilman's The Pharmacological Basis of Therapeutics and Katzung's Basic and Clinical Pharmacology chapters on opioid agonists, antagonists, and analgesic pharmacology.

List four major adverse effects of Morphine, and categorize them based on whether tolerance develops to them during long-term therapy.

Reading File

Finding Sources

Searching the Web

morphine adverse effects tolerance develops constipation miosis standard pharmacology

Major adverse effects of morphine and tolerance during long-term therapy

Adverse effect	Does tolerance develop?
Respiratory depression	Yes. Tolerance develops, though respiratory depression remains dangerous with dose escalation, overdose, or co-administration of sedatives.
Sedation/drowsiness	Yes. It usually diminishes with continued use.
Nausea and vomiting	Yes, usually. Tolerance commonly develops after a few days of therapy.
Constipation	No or minimal tolerance. It tends to persist throughout therapy and usually requires prophylactic bowel management.

Two other classic morphine effects with little or no tolerance are:

Miosis
Urinary retention may improve with tolerance, but can persist, especially in susceptible patients.

Exam point: Tolerance develops to morphine's analgesia, euphoria, sedation, nausea/vomiting, and respiratory-depressant actions. Little or no tolerance develops to miosis and constipation.

References: Katzung's Basic and Clinical Pharmacology, 16th ed., section on opioid agonists and tolerance; Lippincott Illustrated Reviews: Pharmacology, opioid analgesics section.

This is a shared conversation. Sign in to Orris to start your own chat.